Here's the recent articles submitted by mdnews line
Articles By mdnews line
Page: << < [1] > >>
Major Breakthrough: Five-year Survival In Nsclc Patients Treated With First-line Pembrolizumab
Submitted as: MD Newsline
Discover the groundbreaking real-world study on Pembrolizumab for non-small cell lung cancer (NSCLC)! With a 5-year survival rate of 26.9%, this treatment is changing the game for NSCLC patients. Learn how factors like PD-L1 expression, age, and ECOG-PS impact survival. Read the full analysis now!(read
entire article)
View : 41 Times
Category : Health
